Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PD-L1/IDO Peptide Vaccine · 1 trial · 4 indications
Safety and toxicity will be evaluated according to Common Terminology Criteria for Adverse Events version 5.0 and pre-defined treatment-limiting toxicities.
| Arm | Type | Description |
|---|---|---|
| Treatment (IO102-IO103, pembrolizumab) | EXPERIMENTAL | Patients receive PD-L1/IDO peptide vaccine SC and pembrolizumab IV on study. Patients also undergo CT and/or CT/PET and collection of blood samples throughout the trial. |
| Name | Type | Description |
|---|---|---|
| PD-L1/IDO Peptide Vaccine | BIOLOGICAL | Given SC |
| Pembrolizumab | BIOLOGICAL | Given IV |
Inclusion Criteria: * Adults \>= 18 years of age * Histologically confirmed high-risk NMIBC (T1, high-grade Ta, or carcinoma in situ \[CIS\]/Tis). Mixed histologies are allowed if predominantly transitional cell histology. Archival tissue or planned cystoscopy within 28 day of planned initiation of...
PD-L1, PD-L2 peptides with Montanide ISA51 is an investigational peptide vaccine being studied for high risk non-muscle invasive bladder urothelial carcinoma and chronic lymphocytic leukemia. It is also known as PD-L1/IDO Peptide Vaccine and is developed by IO Biotech, Inc. (IOBT).
PD-L1, PD-L2 peptides with Montanide ISA51 targets PD-L1 and PD-L2, which are immune checkpoint proteins. By vaccinating against these targets, the therapy aims to stimulate an immune response against cancer cells that express these proteins.
PD-L1, PD-L2 peptides with Montanide ISA51 is developed by IO Biotech, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker IOBT. The company is conducting clinical trials to evaluate the vaccine in oncology indications.
PD-L1, PD-L2 peptides with Montanide ISA51 is in Phase 2 clinical development. It is investigational and not yet approved by regulatory authorities. The vaccine is being studied in patients with high risk non-muscle invasive bladder cancer and chronic lymphocytic leukemia.
PD-L1, PD-L2 peptides with Montanide ISA51 has been studied in two clinical trials. NCT03939234, a completed Phase 2 trial in chronic lymphocytic leukemia, enrolled 19 patients in Denmark. NCT05843448, a recruiting Phase 1 trial, is evaluating the vaccine with pembrolizumab in non-muscle invasive bladder cancer in the United States.
Yes, PD-L1, PD-L2 peptides with Montanide ISA51 is also known as PD-L1/IDO Peptide Vaccine. The alternative name reflects the vaccine's inclusion of IDO peptides, which are being studied for their immune-modulatory effects in cancer treatment.